An observational study in Cervical Cancer Screening, Gynecologic Cancers and Treatment Compliance, sponsored by Tata Memorial Hospital. Recruiting at 2 sites in India. Open to female participants. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Tata Memorial Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Patient Compliance with a site in India — 2 open to participants now, 2 under way, none of them phase 3. Patient Compliance · India.
Among the 13 studies in Patient Compliance with a site in India, this one is the only one that started in 2021, is one of 6 observational ones, and was the 12th registered.
752 studies on the registry are indexed under Patient Compliance; 72 are open to participants now.
Browse Patient Compliance studies →2 of the 13 studies in Patient Compliance with a site in India are open now. Recruiting first, the newest first:
Tata Memorial Hospital · Sites in India
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 45 Patient Compliance studies recruiting now, 25 (56%) set no upper age limit and 13 (29%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 618 is above the median of 184 across 208 observational studies indexed under Patient Compliance.
Median enrollment 362 across the 7 interventional studies, 484 across the 6 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
Tata Memorial Hospital is the lead sponsor of 99 studies on the registry; 21 are open to participants now.
Tata Memorial Hospital has 6 studies filed under Patient Compliance — fewer than ten, so there is no comparison to draw.
1 of the studies in Patient Compliance with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400809Tata Memorial HospitalCervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study. | 2027-06-14 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Patient Compliance with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+/- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and/or concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.
As a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.
Each of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.
Those centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and /or concurrent chemotherapy over a period of 6 months.
Investigator intend to use electronic case record form (e-CRF) created using on line portal (google e-forms) wherein details of patients treated within the 6 month period will be captured. Google e-CRF will be available to all participating centres free of charge and has ease of access for filling details on both computer, tablets or mobile phone platforms. The e-form is user friendly and provides automated excel output and basic trends of responses and is ideal to be used across busy departments and low resource settings.
To maintain data security, no patient identifying information will be collected. Each institution will be provided an institution id and name identifiers will not be used. Similarly a code will be generated for each of the patient and details of that code will remain with the parent institution.
The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned.
Furthermore any cases referred to the institution for brachytherapy alone will also be included.
The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with proven cervical cancer wherein either radical, or palliative radiation with or without concurrent or systemic chemotherapy is planned.
Furthermore any cases referred to the institution for brachytherapy alone will also be included.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy planned.
Other: Not applicable- observational study
Compliance to Cervical Cancer Chemoradiation treatment guidelines
report on institutional compliance to National Cancer Grid cervical cancer guidelines for chemo-radiation.
To report praportion of patients with No deviation, Major \& Minor Deviation and unacceptable deviation for chemoradiation guidlines.
Time frame: 3 Months
To report on factors impacting compliance to standard guidelines
Time frame: 3years
To report adequacy of infrastructural and manpower requirements for optimal treatment of cervical cancer in NCG centres and corresponding state of origin
Time frame: 3 years
To compute relative risk of suboptimal treatment for cervical cancer in reference to infrastructural and manpower deficits
Time frame: 3 years
Plan to share: Undecided
Started Feb 2021 (actual). Primary completion is estimated for Mar 2026, 61 months after the start.
Of 55 non-industry observational studies under Patient Compliance, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 61 months is above that.
Counting every sponsor, half of 65 studies reached it within 23 months; a quarter within 10 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Hospital